terça-feira, 6 de outubro de 2026
PesquisarExplore
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· April 17, 2026

Ripple (XRP) Hits $1.50: Here’s What $1,000 Invested in XRP Today Could Be Worth by Year End

View original at finance.yahoo.com
Ripple (XRP) Hits $1.50: Here’s What $1,000 Invested in XRP Today Could Be Worth by Year End Quick Read At $1.50, $1,000 buys roughly 667 XRP, and even the conservative XRP price prediction of $2.80 by year-end would turn that into $1,867—an 87% return in eight months…
Opening lines of the source · short snapshot — read the full document at the original

O que extraímos desta fonte

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • XRP reaching $2.80 by year-end would turn $1,000 investment into $1,867—an 87% return in eight months

    60% confidence
  • XRP year-end price target of $2.80

    60% confidence
  • At $1.50, $1,000 buys roughly 667 XRP

    60% confidence
  • 60% odds of CLARITY Act passage

    60% confidence
  • CLARITY Act expected to reach Senate Banking Committee vote in late April or early May

    60% confidence
  • A $1,000 investment in XRP at $0.50 in November 2024 turned into over $7,300 when the token hit $3.65 in July 2025

    60% confidence
  • For XRP to reach $5.00, it needs the CLARITY Act to pass, Bitcoin to break back above $100,000, and institutional money to rotate into altcoins

    60% confidence

Data points we hold from this source

XRP · weekly inflows119.6 USD
O que sabemos · a inteligência por trás desta página
Ao vivo do substrato
O que estamos a ver
Obesity and Immunology Readouts, Big Pharma M&A and AI-Designed Drugs Converge Into a Q4 2026 Catalyst Wave
Late-stage data and deal activity are clustering ahead of Q4 2026. Novo Nordisk's CagriSema won Best Abstract at EASD 2026 for its brain and body (fMRI/MRI) data, Lilly showed ADtouch results for EBGLYSS and agreed to buy Merida Biosciences for $2.9B, and Merck's tulisokibart hit its Phase 2b endpoints. A key regulatory catalyst follows: the FDA PDUFA date for the ivonescimab BLA on 2026-11-14. AI-designed rentosertib showing anti-aging effects adds a speculative AI-drug-discovery thread, while QAIAx's microcities trial and QIII pilot (planned 2027-01-01) are peripheral, forecast-only items.
A nossa leitura dos dados ›
Sinais que acompanhamos
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Padrões que observamos ›
Onde as fontes divergem
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
Sinalizamos conflitos abertamente ›
Verificado recentemente
✓ Verificado com a fonte original
4,985
factos rastreados à sua fonte — e sinalizamos os que não se confirmam.
101 entidades acompanhadas4,985 factos verificados com a fonte5,351 documentos-fonte arquivados
Consulte estes dados → isubstrate.com